

## Paradoxical Cortisol Response to Dexamethasone in Corticotroph Microadenoma: A Useful Feature of Underlying Cyclic Hormonogenesis

Sir,

Endogenous Cushing's syndrome (CS) was diagnosed in a 22-year-old lady with new-onset diabetes mellitus and oligomenorrhea according to the clinical practice guideline of the Endocrine Society [Table 1]. She declined bilateral inferior petrosal sinus sampling (BIPSS). Hormonal parameters at her subsequent follow-up (FU) visits have been summarized in Table 1. Owing to her minimal symptoms, she refused both surgery and ketoconazole therapy. No endogenous hypercortisolemia could be documented during her last visit in December, 2019.

In CD, the setpoint of feedback inhibition of glucocorticoid (GC) on adrenocorticotrophic hormone (ACTH) release from corticotrophs is elevated and more than 50% suppression of serum cortisol following high-dose dexamethasone suppression test (HDDST) is seen in 90% of microadenomas and 50% of macroadenomas. Primary pigmented nodular adrenocortical disease (PPNAD) is characterized by paradoxical rise of endogenous cortisol secretion following

dexamethasone administration in about 69-75% of cases. Such paradoxical response may also be seen in about 20% cases of adrenal adenoma and very rarely in CD, particularly in corticotroph macroadenoma, and has never been reported in microadenoma.<sup>[1,2]</sup> We noticed progressive rise of dexamethasone suppression test (DST) cortisol with an increasing dose of dexamethasone, from 1 mg-overnight DST (ONDST) to low dose DST to HDDST during her initial visit, which prompted us to perform the Liddle's test. Paradoxical rise of ACTH following GC administration in CD was demonstrated long back and a number of postulations like periodic hormonogenesis (with purely fortuitous post-dexamethasone response), GC receptor overexpression on pituitary corticotrophs and, dual feedback mechanisms were put forward.<sup>[1,3]</sup> Cyclic CS is an unusual form of CS, wherein periodic endogenous excess cortisol synthesis is interspersed by episodes of normal/suppressed cortisol secretion. Endogenous hypercortisolemia was documented at the initial and second FU visits, but not at first and third FU visits, suggesting cyclic CS in this lady. Endogenous hypercortisolemia

**Table 1: Summary of investigation at initial presentation and follow-up visits**

| Date                                   | Parameters   | Patient's value  | Reference value   |
|--|--|--|---|
| Hormonal evaluation at initial visit   |  |  |   |
| 09/08/18                               | Free thyroxin (FT4)  | 1.06 ng/dl   | 0.8-1.8 ng/dl   |
|  | Thyroid stimulating hormone (TSH)                                      | 4.33 mIU/L   | 0.7-4.5 mIU/L   |
| 09/08/18                               | 8:00 AM serum cortisol   | 23.42 mcg/dl   | 6.2-19.4 mcg/dl   |
| 09/08/18                               | 8:00 AM plasma ACTH (iced sample)                                      | 12.4 pg/ml   | 7.2-63.3 pg/ml  |
| 14/08/18                               | Midnight sleeping serum cortisol                                       | 10.94 mcg/dl   | >1.8 mcg/dl: 100% sensitivity for CS>7.5 mcg/dl: 87% specificity for CS                                 |
| 15/08/18                               | Overnight 1 mg dexamethasone suppression test (DST) cortisol           | 2.61 mcg/dl  | >1.8 mcg/dl: 95% sensitivity and 80% specificity for CS   |
| 16/08/18-18/08/18                      | Low dose (0.5 mg QDS for 2 days) DST cortisol                          | 13.47 mcg/dl   | >1.8 mcg/dl: 96% sensitivity and 70% specificity for CS   |
| 19/0818-21/08/18                       | High dose (2 mg QDS for 2 days) DST cortisol                           | 24.31 mcg/dl   | >50% suppression from basal value: 80% sensitivity for CD   |
| 28/08/18                               | 8:00 AM serum cortisol   | 23.5 mcg/dl  | >50% rise from baseline is considered positive test   |
| 28/08/18-02/09/18                      | Liddle's test cortisol   | 44.63 mcg/dl   |   |
| 12/09/18                               | 8:00 AM serum cortisol   | 22.3 mcg/dl  | ACTH increase greater than 50% and a cortisol rise greater than 20% over baseline values are seen in CD |
|  | 8:00 AM plasma ACTH (iced sample)                                      | 65.9 pg/ml   |   |
|  | Serum cortisol (15 min post Inj AVP)                                   | 29.4 mcg/dl  |   |
|  | Plasma ACTH (15 min post Inj. AVP)                                     | 111.2 pg/ml  |   |
|  | Dynamic magnetic resonance imaging (MRI) of hypothalamo-pituitary area | Hypoenhancing area measuring 6 mm (transverse) X 4 mm (craniocaudal) in the right half of the pituitary gland with deviation of the infundibulum towards left          |   |
|  | Computed tomography (CT) scan of the abdomen                           | Both the adrenal glands appeared slightly bulky  |   |
|  | CT scan of neck and chest  | Negative for any space-occupying lesion  |   |
|  | Genetic analysis for protein kinase A regulatory subunit 1A (PRKARIA)  | The entire coding region and exon-intron boundaries of PRKARIA were amplified by polymerase chain reaction (PCR) and sequenced. No pathogenic mutation was identified. |   |
| Hormonal evaluation at first FU visit  |  |  |   |
| 14/01/19                               | 8:00 AM serum cortisol   | 7.72 mcg/dl  | 6.2-19.4 mcg/dl   |
| 14/01/19                               | 8:00 AM plasma ACTH (iced sample)                                      | 43.8 pg/ml   | 7.2-63.3 pg/ml  |
| 22/01/19                               | 24-hour urinary free cortisol  | 241.78 mcg/day   | 58-403 mcg/day  |
| 24/01/19                               | Overnight 1 mg DST cortisol  | 0.90 mcg/dl  |   |
| 25/01/19-27/01/19                      | High dose (2 mg QDS for 2 days) DST cortisol                           | 0.78 mcg/dl  |   |
| Hormonal evaluation at second FU visit |  |  |   |
| 18/07/19                               | 24-hour urinary free cortisol  | 687 mcg  | 58-403 mcg/day  |
| 19/07/19                               | 24-hour urinary free cortisol  | 714 mcg  | 58-403 mcg/day  |
| 20/07/19                               | 8:00 AM serum cortisol   | 22.34 mcg/dl   | 4.3-22.4 mcg/day  |
| 20/07/19                               | 8:00 AM plasma ACTH (iced sample)                                      | 24.4 pg/ml   |   |
| 20/07/19-22/07/19                      | Low dose (0.5 mg QDS for 2 days) DST cortisol                          | 16.6 mcg/dl  |   |
| 20/07/19-25/07/19                      | Liddle's test cortisol   | 61 mcg/dl  |   |
| 15/08/19                               | 8:00 AM serum cortisol   | 20.4 mcg/dl  | ACTH increase greater than 50% and cortisol rise greater than 20% over baseline values are seen in CD   |
|  | 8:00 AM plasma ACTH (iced sample)                                      | 85.2 pg/ml   |   |
|  | Serum cortisol (15 min post Inj AVP)                                   | 29.5 mcg/dl  |   |
|  | Plasma ACTH (15 min post Inj. AVP)                                     | 152 pg/ml  |   |
| Hormonal evaluation at third FU visit  |  |  |   |
| 22/12/19                               | 8:00 AM serum cortisol   | 6.1 mcg/dl   | 6.2-19.4 mcg/dl   |
| 22/12/19                               | 8:00 AM plasma ACTH (iced sample)                                      | 25.2 pg/ml   | 7.2-63.3 pg/ml  |
| 28/12/19                               | 24-hour urinary free cortisol  | 101 mcg/day  | 58-403 mcg/day  |
| 4/01/20                                | Overnight 1 mg DST cortisol  | 0.7 mcg/dl   |   |
| 04/01/20-6/01/20                       | High dose (2 mg QDS for 2 days) DST cortisol                           | 0.42 mcg/dl  |   |

subsided spontaneously during the first and third FU visits. An intriguing feature we noticed, was paradoxical cortisol response with dexamethasone during her initial presentation and second FU visit (i.e., during periods of relapse), but adequately suppressed high dose DST cortisol at her first and third FU visits (i.e., during periods of remission). This could be explained by two possibilities: First, the DST tests were performed during the ascending arm of cyclic hormonogenesis and falsely interpreted as positive Liddle's test. Second, the paradoxical cortisol response is seen only during endogenous hypercortisolemia. The presence of a GC positive feedback loop on corticotrophs and simultaneous endogenous hypercortisolemia has been suggested as the underlying cause of such paradoxical response.<sup>[4]</sup> A period of low endogenous cortisol, as seen during the trough of cyclic CD, probably changes the character of pituitary corticotroph adenoma, that eventually develops a positive feedback response to GC only during subsequent hypercortisolemia in the peak phase of cyclic CS. Exogenous GC administration thus results in paradoxical ACTH-dependent rise in cortisol secretion only during endogenous hypercortisolemia (as noticed during initial visit and second FU visit) and preceding episode of hypocortisolemia is an essential prerequisite to trigger ACTH hypersecretion through a positive feedback loop. Progressive rise in DST-cortisol values with incremental doses of dexamethasone during the evaluation of CS may thus point towards cyclical hormonogenesis in ACTH-producing corticotroph microadenoma.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

**Rahin Mahata, Partha Pratim Chakraborty, Anirban Sinha, Animesh Maiti**

Department of Endocrinology and Metabolism, Medical College,  
Kolkata, 88 College Street, Kolkata 73, West Bengal, India

**Address for correspondence:** Dr. Partha Pratim Chakraborty,  
Department of Endocrinology and Metabolism, Super Specialty Block (SSB),  
4<sup>th</sup> Floor, Medical College, 88 College Street, Kolkata 73, Kolkata,  
West Bengal, India.  
E-mail: docparthapc@yahoo.co.in

## REFERENCES

1. Checchi S, Brilli L, Guarino E, Ciuoli C, Di Cairano G, Mazzucato P, *et al.* Cyclic cushing's disease with paradoxical response to dexamethasone. *J Endocrinol Invest* 2005;28:741-5.
2. Lila AR, Sarathi V, Bandgar TR, Shah NS. Paradoxical response to dexamethasone and spontaneous hypocortisolism in Cushing's disease. *BMJ Case Rep* 2013;2013:bcr2012008035.
3. Fehm HL, Voight KH, Lang RE. Paradoxical ACTH response to glucocorticoids in Cushing's disease. *N Engl J Med* 1977;297:904-7.
4. Seki Y, Morimoto S, Saito F, Takano N, Kimura S, Yamashita K, *et al.* ACTH-dependent cyclic cushing syndrome triggered by glucocorticoid excess through a positive-feedback mechanism. *J Clin Endocrinol Metab* 2019;104:1788-91.

Submitted: 25-Feb-2020

Accepted: 03-Mar-2020

Published: 30-Apr-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

| Access this article online   |   |
|--|---|
| <b>Quick Response Code:</b><br> | <b>Website:</b><br><a href="http://www.ijem.in">www.ijem.in</a> |
|  | <b>DOI:</b><br>10.4103/ijem.IJEM_95_20                          |

**How to cite this article:** Mahata R, Chakraborty PP, Sinha A, Maiti A. Paradoxical cortisol response to dexamethasone in corticotroph microadenoma: A useful feature of underlying cyclic hormonogenesis. *Indian J Endocr Metab* 2020;24:220-2.

© 2020 Indian Journal of Endocrinology and Metabolism | Published by Wolters Kluwer - Medknow